Baddenhausen S, Lutz B, Hofmann C
Front Mol Neurosci. 2024; 17:1379889.
PMID: 38660383
PMC: 11042029.
DOI: 10.3389/fnmol.2024.1379889.
Mohammad S, Mousa R, Gebril S, Mohamed Masoud K, Radwan R
Forensic Toxicol. 2023; 42(1):7-17.
PMID: 37573525
PMC: 10808145.
DOI: 10.1007/s11419-023-00670-0.
Levichev A, Faumont S, Berner R, Purcell Z, White A, Chicas-Cruz K
Curr Biol. 2023; 33(9):1625-1639.e4.
PMID: 37084730
PMC: 10175219.
DOI: 10.1016/j.cub.2023.03.013.
Hirsch S, Hinden L, Naim M, Baraghithy S, Permyakova A, Azar S
J Control Release. 2022; 353:254-269.
PMID: 36442615
PMC: 9900386.
DOI: 10.1016/j.jconrel.2022.11.040.
Braunscheidel K, Okas M, Floresco S, Woodward J
Psychopharmacology (Berl). 2021; 239(5):1337-1347.
PMID: 34291308
PMC: 9885490.
DOI: 10.1007/s00213-021-05914-8.
: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome.
Hirsch S, Tam J
Toxins (Basel). 2019; 11(5).
PMID: 31096702
PMC: 6563239.
DOI: 10.3390/toxins11050275.
Cannabinoid Ligands and Alcohol Addiction: A Promising Therapeutic Tool or a Humbug?.
Kleczkowska P, Smaga I, Filip M, Bujalska-Zadrozny M
Neurotox Res. 2015; 29(1):173-96.
PMID: 26353844
PMC: 4701763.
DOI: 10.1007/s12640-015-9555-7.
Blockade of CB1 receptors prevents retention of extinction but does not increase low preincubated conditioned fear in the fear incubation procedure.
Pickens C, Theberge F
Behav Pharmacol. 2013; 25(1):23-31.
PMID: 24346290
PMC: 4494125.
DOI: 10.1097/FBP.0000000000000020.
Endocannabinoids promote cocaine-induced impulsivity and its rapid dopaminergic correlates.
Hernandez G, Oleson E, Gentry R, Abbas Z, Bernstein D, Arvanitogiannis A
Biol Psychiatry. 2013; 75(6):487-98.
PMID: 24138924
PMC: 3943889.
DOI: 10.1016/j.biopsych.2013.09.005.
Rimonabant precipitates anxiety in rats withdrawn from palatable food: role of the central amygdala.
Blasio A, Iemolo A, Sabino V, Petrosino S, Steardo L, Rice K
Neuropsychopharmacology. 2013; 38(12):2498-507.
PMID: 23793355
PMC: 3799070.
DOI: 10.1038/npp.2013.153.
Rimonabant, gastrointestinal motility and obesity.
Sun Y, Chen J
Curr Neuropharmacol. 2013; 10(3):212-8.
PMID: 23449551
PMC: 3468875.
DOI: 10.2174/157015912803217297.
Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats.
Wright F, Rodgers R
Psychopharmacology (Berl). 2012; 226(2):415-31.
PMID: 23142959
DOI: 10.1007/s00213-012-2916-5.
The endocannabinoid system: role in energy regulation.
Gamage T, Lichtman A
Pediatr Blood Cancer. 2011; 58(1):144-8.
PMID: 22076835
PMC: 3696506.
DOI: 10.1002/pbc.23367.
Cannabinoid facilitation of behavioral and biochemical hedonic taste responses.
De Luca M, Solinas M, Bimpisidis Z, Goldberg S, Di Chiara G
Neuropharmacology. 2011; 63(1):161-8.
PMID: 22063718
PMC: 3705914.
DOI: 10.1016/j.neuropharm.2011.10.018.
Extinction learning of rewards in the rat: is there a role for CB1 receptors?.
Hernandez G, Cheer J
Psychopharmacology (Berl). 2011; 217(2):189-97.
PMID: 21519986
PMC: 3161161.
DOI: 10.1007/s00213-011-2275-7.
The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.
Kunos G, Tam J
Br J Pharmacol. 2011; 163(7):1423-31.
PMID: 21434882
PMC: 3165952.
DOI: 10.1111/j.1476-5381.2011.01352.x.
The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior.
Randall P, Vemuri V, Segovia K, Torres E, Hosmer S, Nunes E
Pharmacol Biochem Behav. 2010; 97(1):179-84.
PMID: 20713079
PMC: 3522179.
DOI: 10.1016/j.pbb.2010.07.021.
Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists.
McLaughlin P, Winston K, Swezey L, Vemuri V, Makriyannis A, Salamone J
Pharmacol Biochem Behav. 2010; 96(1):75-81.
PMID: 20403373
PMC: 5426058.
DOI: 10.1016/j.pbb.2010.04.009.
Endocannabinoid signaling in neurotoxicity and neuroprotection.
Pope C, Mechoulam R, Parsons L
Neurotoxicology. 2009; 31(5):562-71.
PMID: 19969019
PMC: 2891218.
DOI: 10.1016/j.neuro.2009.12.002.
Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113.
Sink K, Vemuri V, Wood J, Makriyannis A, Salamone J
Pharmacol Biochem Behav. 2008; 91(3):303-6.
PMID: 18703081
PMC: 2806679.
DOI: 10.1016/j.pbb.2008.07.013.